Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Researchers linked higher weight loss after initiating antiobesity meds to lower risk for revision of hip and knee replacement.
It seems like no matter what I do, I can't lose weight. Most of my family members struggle with their weight too. Do our ...
Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of ...
"The size is significant. We're talking about 900 million patients that could benefit from Mounjaro," Montarce said at the ...
MarketBeat on MSN1h
Despite Challenges Novo Nordisk Plans to Crush GLP-1 CompetitorsNovo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...
Most HHS workers were emailed an offer to leave their job for as much as $25,000 as part of President Trump’s government cuts ...
Howl-lelujah! Dogs and humans are fatter than ever — it’s no surprise that overweight people tend to have overweight dogs.
Avocados, fatty fish, salad dressing, nuts and yogurt are high-fat foods that can support weight loss. Fat provides energy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback